Annonaceous Acetogenin Mimic AA005 Inhibits the Growth of TNBC MDA‐MB‐468 Cells by Altering Cell Energy Metabolism
Bao‐Bao Yu,Hao Yuan,Yun‐Cong Chen,Dan‐Xia Zhou,Zhen‐Ji Gan,Jie Wang,Jian‐Xin Li,Zhu‐Jun Yao,Bao-Bao Yu,Yun-Cong Chen,Dan-Xia Zhou,Zhen-Ji Gan,Jian-Xin Li,Zhu-Jun Yao
DOI: https://doi.org/10.1002/cbic.202200250
IF: 3.2
2022-06-10
ChemBioChem
Abstract:AA005, a structurally simplified mimic of natural Annonaceous acetogenins, presents outstanding properties with impressive cytotoxicity and cell‐type selective actions. The present study aimed at evaluating the potential of AA005 as a therapeutic agent for Triple‐negative breast cancer (TNBC). AA005 potently inhibited the growth of TNBC cells at 50 nM level. Inspired by the finding of the phosphatase and tensin homolog (PTEN) tumor suppressor, the effect of AA005 on aerobic glycolysis was investigated in TNBC MDA‐MB‐468 cells. Of note, a short‐term AA005 exposure markedly suppressed the mitochondrial function in MDA‐MB‐468 cells, thus activating the aerobic glycolysis to lessen the risk of decreased ATP generation in mitochondria. While, prolonging the incubation time of AA005 obviously weakened the aerobic glycolysis in the cells. This was in part attributed to the PI3K‐AKT pathway inactivation and subsequent declined glucose uptake. As a consequence, the energy supply was completely cut down from the two major energy‐producing pathways. Further experiments also showed that AA005 resulted in irreversible damage on cell activity including cell cycle and growth, inducing mitochondrial oxidative stress and ultimately leading to cell death. In addition, the in vivo therapeutic efficacy of AA005 was proved on 4T1 xenograft tumor mice model. Our data demonstrated that AA005 exhibited a great potential for future clinical applications in TNBC therapy.
biochemistry & molecular biology,chemistry, medicinal